Metabolic Effects of Dietary Supplementation With Lactobacillus Reuteri DSM 17938 - a Randomised Placebo Controlled Proof-of-concept Study in Type 2 Diabetes
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2013 New trial record